Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder

Brigette Vaughan, Joerg Fegert, Christopher J. Kratochvil

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

Background: Atomoxetine, an inhibitor of, the presynaptic transporter of norepinephrine, was approved for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children aged 6 years and older, adolescents and adults in the USA in 2002, and in Europe, first in the UK and then by mutual recognition in several countries during 2003 and 2004. Since that time, the use of atomoxetine has spread globally and extensive additional research has been conducted evaluating its efficacy and safety. Objective: The objective of this review is to provide a summary of the available data on atomoxetine, with an emphasis on postmarketing clinical research, which is helping to clarify the role of this agent in ADHD pharmacotherapy. Methods: Recent as well as long-term safety and efficacy data are reviewed, with an emphasis on comparison with long-acting psychostimulants, ADHD in special populations and in patients with psychiatric comorbidities. Results/conclusion: Atomoxetine is an effective acute and long-term pharmacotherapy for ADHD, and may play a particular role in the treatment of patients with comorbid disorders and those who have failed or are unable to tolerate stimulants.

Original languageEnglish (US)
Pages (from-to)669-676
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Volume10
Issue number4
DOIs
StatePublished - Mar 1 2009

Fingerprint

Attention Deficit Disorder with Hyperactivity
Norepinephrine Plasma Membrane Transport Proteins
Safety
Drug Therapy
Therapeutics
Research
Psychiatry
Comorbidity
Atomoxetine Hydrochloride
Population

Keywords

  • ADHD
  • Atomoxetine
  • Pharmacotherapy
  • Stimulant

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. / Vaughan, Brigette; Fegert, Joerg; Kratochvil, Christopher J.

In: Expert Opinion on Pharmacotherapy, Vol. 10, No. 4, 01.03.2009, p. 669-676.

Research output: Contribution to journalReview article

@article{4d0979300dfb441084b6cd8cc6014577,
title = "Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder",
abstract = "Background: Atomoxetine, an inhibitor of, the presynaptic transporter of norepinephrine, was approved for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children aged 6 years and older, adolescents and adults in the USA in 2002, and in Europe, first in the UK and then by mutual recognition in several countries during 2003 and 2004. Since that time, the use of atomoxetine has spread globally and extensive additional research has been conducted evaluating its efficacy and safety. Objective: The objective of this review is to provide a summary of the available data on atomoxetine, with an emphasis on postmarketing clinical research, which is helping to clarify the role of this agent in ADHD pharmacotherapy. Methods: Recent as well as long-term safety and efficacy data are reviewed, with an emphasis on comparison with long-acting psychostimulants, ADHD in special populations and in patients with psychiatric comorbidities. Results/conclusion: Atomoxetine is an effective acute and long-term pharmacotherapy for ADHD, and may play a particular role in the treatment of patients with comorbid disorders and those who have failed or are unable to tolerate stimulants.",
keywords = "ADHD, Atomoxetine, Pharmacotherapy, Stimulant",
author = "Brigette Vaughan and Joerg Fegert and Kratochvil, {Christopher J.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1517/14656560902762873",
language = "English (US)",
volume = "10",
pages = "669--676",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder

AU - Vaughan, Brigette

AU - Fegert, Joerg

AU - Kratochvil, Christopher J.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Background: Atomoxetine, an inhibitor of, the presynaptic transporter of norepinephrine, was approved for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children aged 6 years and older, adolescents and adults in the USA in 2002, and in Europe, first in the UK and then by mutual recognition in several countries during 2003 and 2004. Since that time, the use of atomoxetine has spread globally and extensive additional research has been conducted evaluating its efficacy and safety. Objective: The objective of this review is to provide a summary of the available data on atomoxetine, with an emphasis on postmarketing clinical research, which is helping to clarify the role of this agent in ADHD pharmacotherapy. Methods: Recent as well as long-term safety and efficacy data are reviewed, with an emphasis on comparison with long-acting psychostimulants, ADHD in special populations and in patients with psychiatric comorbidities. Results/conclusion: Atomoxetine is an effective acute and long-term pharmacotherapy for ADHD, and may play a particular role in the treatment of patients with comorbid disorders and those who have failed or are unable to tolerate stimulants.

AB - Background: Atomoxetine, an inhibitor of, the presynaptic transporter of norepinephrine, was approved for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children aged 6 years and older, adolescents and adults in the USA in 2002, and in Europe, first in the UK and then by mutual recognition in several countries during 2003 and 2004. Since that time, the use of atomoxetine has spread globally and extensive additional research has been conducted evaluating its efficacy and safety. Objective: The objective of this review is to provide a summary of the available data on atomoxetine, with an emphasis on postmarketing clinical research, which is helping to clarify the role of this agent in ADHD pharmacotherapy. Methods: Recent as well as long-term safety and efficacy data are reviewed, with an emphasis on comparison with long-acting psychostimulants, ADHD in special populations and in patients with psychiatric comorbidities. Results/conclusion: Atomoxetine is an effective acute and long-term pharmacotherapy for ADHD, and may play a particular role in the treatment of patients with comorbid disorders and those who have failed or are unable to tolerate stimulants.

KW - ADHD

KW - Atomoxetine

KW - Pharmacotherapy

KW - Stimulant

UR - http://www.scopus.com/inward/record.url?scp=65649121932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649121932&partnerID=8YFLogxK

U2 - 10.1517/14656560902762873

DO - 10.1517/14656560902762873

M3 - Review article

C2 - 19239401

AN - SCOPUS:65649121932

VL - 10

SP - 669

EP - 676

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 4

ER -